Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety

Hui Luo; Yuanfang Li; W. Wang; Zhanmei Wang; Xia Yuan; Dong Ma; Fan Wang; D. S. Zhang; Dongdong Lin; Yingcheng Lin; Jun Jia; Xiao Hu; Jiewen Peng; Rui‐Hua Xu

doi:10.1093/annonc/mdw101

Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety

Hui Luo(Sun Yat-sen University), Yuanfang Li(Sun Yat-sen University), W. Wang(First People's Hospital of Foshan), Zhanmei Wang(State Key Laboratory of Oncology in South China), Xia Yuan(Huizhou Central People's Hospital), Dong Ma(Guangdong General Hospital), Fan Wang(Sun Yat-sen University), D. S. Zhang(Sun Yat-sen University), Dongdong Lin(Jiangmen Central Hospital), Yingcheng Lin(Cancer Hospital of Shantou University Medical College), Jun Jia(Dongguan People’s Hospital), Xiao Hu(Tumor Hospital of Guangxi Medical University), Jiewen Peng(Zhongshan People's Hospital), Rui‐Hua Xu(Sun Yat-sen University)

Annals of Oncology

March 4, 2016

10.1093/annonc/mdw101

Cited by 90

Abstract

Related Papers

No related papers found

Powered by citation graph analysis